PMID- 26414653
OWN - NLM
STAT- MEDLINE
DCOM- 20160909
LR  - 20220311
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 32
IP  - 1
DP  - 2016
TI  - Perioperative blood loss and gastrointestinal tolerability of etoricoxib and 
      diclofenac in total hip arthroplasty (ETO-DIC study): a single-center, 
      prospective double-blinded randomized controlled trial.
PG  - 37-47
LID - 10.1185/03007995.2015.1100987 [doi]
AB  - OBJECTIVE: Non-selective NSAIDs can cause serious gastrointestinal side-effects. 
      Selective COX-2 blockers are a reasonable alternative for pain treatment. They do 
      not seem to affect platelet function and consequently cause a lower perioperative 
      blood loss than non-selective NSAIDs. This study compared etoricoxib and 
      diclofenac during a perioperative (9 days) period after THA to investigate total 
      blood loss and gastrointestinal tolerability. The hypothesis was that etoricoxib 
      is superior to diclofenac. METHODS: A total of 100 patients (50 in each group) 
      were included in this trial. Etoricoxib (90 mg) was administered once and 
      diclofenac sodium (75 mg) twice daily for 9 days. Total blood loss during and 
      after primary cementless THA was detected. The rate of adverse events (AEs) and 
      serious adverse events (SAEs) was analyzed to detect gastrointestinal 
      tolerability. RESULTS: The mean total blood loss (calculated) was 1548 +/- SD 
      468 ml in the etoricoxib (ETO) group and 1649 (SD 547) ml in the diclofenac (DIC) 
      group. The mean duration of THA was 81 min (SD 29) in the DIC and 75 min (SD 30) 
      in the ETO group. Hence, the mean calculated total blood loss was 101 ml higher 
      in the DIC group. This difference was not statistically significant (p = 0.334). 
      Fifty-six patients (28 in each group) received a cell saver retransfusion, but 
      only one patient (ETO group) needed an additional red blood cell transfusion. The 
      hidden blood loss was 1067 ml (SD 603) in the DIC group and 999 ml (SD 378) in 
      the ETO group. The gastrointestinal tolerability (number of adverse and serious 
      adverse events) was not significantly different between groups. CONCLUSION: There 
      was no statistically significant difference in perioperative blood loss after 
      primary THA under etoricoxib (90 mg) compared to diclofenac (75 mg). Furthermore, 
      no gastrointestinal superiority of etoricoxib could be detected during a short 
      period of 9 days.
FAU - Winkler, Sebastian H
AU  - Winkler SH
AD  - a a Department of Orthopedic Surgery , Regensburg University Medical Center , Bad 
      Abbach , Germany.
FAU - Barta, Sabine
AU  - Barta S
AD  - b b Munchner Studienzentrum, Klinikum rechts der Isar der Technischen Universitat 
      Munchen , Munich , Germany.
FAU - Kehl, Victoria
AU  - Kehl V
AD  - c c Institute for Medical Statistics and Epidemiology, Technische Universitat , 
      Munich , Germany.
FAU - Schroter, Christoph
AU  - Schroter C
AD  - a a Department of Orthopedic Surgery , Regensburg University Medical Center , Bad 
      Abbach , Germany.
FAU - Wagner, Ferdinand
AU  - Wagner F
AD  - a a Department of Orthopedic Surgery , Regensburg University Medical Center , Bad 
      Abbach , Germany.
FAU - Grifka, Joachim
AU  - Grifka J
AD  - a a Department of Orthopedic Surgery , Regensburg University Medical Center , Bad 
      Abbach , Germany.
FAU - Springorum, Hans Robert
AU  - Springorum HR
AD  - a a Department of Orthopedic Surgery , Regensburg University Medical Center , Bad 
      Abbach , Germany.
FAU - Craiovan, Benjamin
AU  - Craiovan B
AD  - a a Department of Orthopedic Surgery , Regensburg University Medical Center , Bad 
      Abbach , Germany.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20151119
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Sulfones)
RN  - 144O8QL0L1 (Diclofenac)
RN  - WRX4NFY03R (Etoricoxib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - *Arthroplasty, Replacement, Hip
MH  - Cyclooxygenase Inhibitors/*adverse effects
MH  - Diclofenac/*adverse effects
MH  - Double-Blind Method
MH  - Etoricoxib
MH  - Female
MH  - Gastrointestinal Tract/*drug effects
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Pyridines/*adverse effects
MH  - Sulfones/*adverse effects
OTO - NOTNLM
OT  - Diclofenac
OT  - Etoricoxib
OT  - Perioperative blood loss
OT  - Total hip arthroplasty
EDAT- 2015/09/29 06:00
MHDA- 2016/09/10 06:00
CRDT- 2015/09/29 06:00
PHST- 2015/09/29 06:00 [entrez]
PHST- 2015/09/29 06:00 [pubmed]
PHST- 2016/09/10 06:00 [medline]
AID - 10.1185/03007995.2015.1100987 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2016;32(1):37-47. doi: 10.1185/03007995.2015.1100987. Epub 
      2015 Nov 19.